Previous 10 | Next 10 |
home / stock / mrk / mrk articles
ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrang...
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouragin...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday. The Dow traded down 1.55% to 3...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Wednesday, Immutep Limited (NASDAQ:IMMP) released preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) P...
Wall Street analysts forecast that Merck (NYSE: MRK) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Famed COVID-19 vaccine maker Moderna Inc (NASDAQ:MRNA) has decided to pause its plans to construct a vaccine manufacturing...
News, Short Squeeze, Breakout and More Instantly...
How one employee's upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work she's done across industries. As a young...
Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced upcoming data presentations and programming at the 25 th International ...
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates Merck (NYSE: MRK), known as MSD outside of t...